Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
News & Events

Press Releases

Upcoming Events

Media Contact:
Nancy Pecota
Chief Financial Officer
Assistant: Lyn Carlos
Phone: 510-265-8800
E-mail: investor@aradigm.com

Latest News

Mullti-million Dollar DTRA Funding for Biodefense Research with Aradigm's Inhaled Ciprofloxacin
[18OCT16]

Aradigm Announces Australian Research Council Funding to Develop Nanotechnologies Targeting Bacterial and Fungal Biofilms
[21AUG16]

Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients
[21AUG16]

Aradigm to Host Analyst Meeting and Webcast on September 26 in New York City
[21AUG16]

Aradigm to Present at the Ladenburg Thalmann 201 Healthcare Conference on September 27th
[20AUG16]

Aradigm Announces Second Quarter 2016 Financial Results
[10AUG16]

Two Presentations on Aradigm's Inhaled Liposomal Ciprofloxacin Programs at the American Thoracic Society 2016 International Conference
[11MAY16]

Aradigm Announces First Quarter 2016 Financial Results
[10MAY16]

Aradigm Corporation Announces First Closing of Private Placement Offering of $23 Million Senior Convertible Notes Due 2021
[26APR16]

Aradigm Corporation Prices Private Placement of Senior Notes
[22APR16]

Aradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency
[17MAR16
]

Aradigm Announces Fourth Quarter 2015 and Full Year Financial Results
[02FEB16
]

Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2016 on February 8
[02FEB16
]

Aradigm Bio Presentation

Aradigm to Host Corporate Update Conference Call on January 6
[05JAN16
]

Aradigm Announces Third Quarter 2015 Financial Results
[11NOV15
]

Aradigm Corporation Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)
[13OCT15
]

Aradigm Thalmann Presentation

Aradigm to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29
[23SEP15
]

Aradigm Corporation Completes Enrollment in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)
[22SEP15
]

Results from Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigm's Liposomal Ciprofloxacin to Be Presented at ICAAC/ICC 2015
[10SEP15
]

Aradigm Announces Second Quarter 2015 Financial Results
[13AUG15
]

Results from Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigm's Liposomal Ciprofloxacin to be Presented at the American Thoracic Society 2015 International Conference
[12MAY15
]

Aradigm Announces First Quarter 2015 Financial Results
May 11, 2015
[11MAY15
]

Aradigm Announces Appointment of Dr. Robert A. Reed as Vice President, Regulatory (Chemistry, Manufacturing and Controls) and Quality
[21APR15
]

Aradigm to Host Key Opinion Leader Breakfast and Webcast on April 23 in New York City
[16APR15
]

Aradigm Announces Fourth Quarter 2014 and Full Year Financial Results
[17MAR15
]

Aradigm Corporation President & CEO Dr. Igor Gonda, Ph.D. to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM's "Health Tech Talk Live"
[27FEB15
]

Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2015 on February 10
[04FEB15
]

Aradigm Granted Key Composition of Matter Patents for Pulmaquin in Europe and Australia
[14JAN15
]

Aradigm to Present at Biotech Showcase 2015 on January 14
[08JAN15
]

Upcoming Events
For a listing of Upcoming Events click here.

 

 

 

 

 

 

 

CONTACT NEWS & EVENTS LEGAL SITE MAP ©2016 Aradigm Corporation. All Rights Reserved.